SCHEMBL41990

SCHEMBL41990

OB(O)c1ccc(Cl)cc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.48
HSD17B10 Q99714 2/20 0.48
TP53 P04637 2/20 0.48
ENPP2 Q13822 1/20 0.44
TDP1 Q9NUW8 3/20 0.43
CYP3A4 P08684 3/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
NR1I2 O75469 1/20 0.42
TTR P02766 1/20 0.42
PGR P06401 1/20 0.42
HSP90AA1 P07900 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
MAPT P10636 1/20 0.42
HSPA5 P11021 1/20 0.42
HPGD P15428 1/20 0.42
CBR1 P16152 1/20 0.42
TBXA2R P21731 1/20 0.42
SLC6A2 P23975 1/20 0.42
AGTR1 P30556 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29375771 1.00 TSHR (0.48) TSHRHSD17B10TP53ENPP2TDP1
SCHEMBL15701857 0.82 TSHR (0.41) TSHRHSD17B10TP53TDP1CYP3A4
SCHEMBL491658 0.80 TSHR (0.48) TSHRHSD17B10TP53ENPP2TDP1
SCHEMBL29376152 0.80 TSHR (0.48) TSHRHSD17B10TP53ENPP2TDP1
SCHEMBL2587772 0.78 HSD17B10 (0.52) TSHRHSD17B10ENPP2TDP1CYP3A4
SCHEMBL29954084 0.78 HSD17B10 (0.52) TSHRHSD17B10ENPP2TDP1CYP3A4
SCHEMBL29825793 0.78 CYP3A4 (0.43) TSHRHSD17B10ENPP2TDP1CYP3A4
SCHEMBL340177 0.78 CA2 (0.42) TP53TDP1LMNAHPGDSMN1; SMN2
SCHEMBL624402 0.78 CYP3A4 (0.43) TSHRHSD17B10ENPP2TDP1CYP3A4
SCHEMBL29954486 0.78 HSD17B10 (0.54) HSD17B10ENPP2CYP3A4TTRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
US-12102715-B1 ROS-responsive liposomes for specific targeting VERILY LIFE SCIENCES LLC (US) 2024-10-01 US claimed
CN-117342907-A Method for preparing phenol by hydroxylation reaction of boric acid derivative in air under no-alkali condition without light catalyst 江西科技师范大学 2024-01-05 CN claimed
US-20230380457-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-30 US claimed
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 EP claimed
US-20230363426-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-16 US claimed
US-11793220-B2 Materials and methods for extending shelf-life of foods JP LABORATORIES, INC. (US) 2023-10-24 US claimed
CN-116916755-A Materials and methods for extending the shelf life of food products JP实验室公司 2023-10-20 CN claimed
US-20220264914-A1 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. 2022-08-25 US claimed
US-10517823-B1 ROS—responsive liposomes for specific targeting VERILY LIFE SCIENCES LLC (US) 2019-12-31 US claimed
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 US claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008101860-A1 NOVEL PROCESS FOR THE PREPARATION OF 5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYL-N-(PIPERIDIN-1-YL)PYRAZOLE-3-CARBOXAMIDE SANDOZ AG (CH) 2008-08-28 WO claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
US-6800784-B1 REACTING AROMATIC COMPOUND CARRYING AT LEAST ONE AMINO GROUP AND LEAVING GROUP WITH ARYLBORONIC ACID OR DERIVATIVE THEREOF, IN AQUEOUS MEDIUM, AND IN PRESENCE OF EFFECTIVE QUANTITY OF PALLADIUM CATALYST RHODIA CHIMIE (FR) 2004-10-05 US claimed
US-6590100-B2 Reacting an aromatic compound bearing a leaving group and an arylboronic acid and/or its derivatives in the presence of a base and an effective amount of a nickel catalyst RHODIA CHIMIE (FR) 2003-07-08 US claimed
US-20020173652-A1 Process for preparing a polyaromatic compound SHASUN PHARMA SOLUTIONS, INC. 2002-11-21 US claimed
WO-1995005081-A1 BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS U.S. BORAX INC. (US) 1995-02-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH TSHR 411/4885HSD17B10 323/4885TP53 2189/4885
US-20020173652-A1 Process for preparing a polyaromatic compound PAH, ALK, ITPA TSHR 4264/4885HSD17B10 2644/4885TP53 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.